

# Driving successful business transformation in life sciences with smarter information management

Effectively address challenges during business restructuring



In the rapidly evolving life sciences industry, corporate restructuring through acquisitions, mergers, and divestitures presents unique information management challenges. As organizations reconfigure to optimize product portfolios, research capabilities, and market reach, they must navigate complex content integration and migration requirements. Effective information management is critical for pharmaceutical companies undergoing structural transformation. Here's why:

- 1 Regulatory compliance continuity** - Maintain uninterrupted GxP compliance throughout organizational transitions by preserving document integrity, audit trails, and validation evidence across integrated systems.
- 2 IP protection** - Secure valuable intellectual property during transition periods, when sensitive research data and patent documentation are most vulnerable to access control gaps.
- 3 Research acceleration** - Eliminate research silos by unifying experimental data, enabling scientists to build upon combined institutional knowledge and avoid duplicating previous work.
- 4 Cost reduction** - Consolidate redundant systems and streamline information workflows to achieve operational efficiencies that directly impact post-restructuring financial performance.

**“Over the last two years, Fresenius Kabi has begun replacing its legacy and acquired document management systems with the new, central document management platform. On average, the company’s IT team can bring new global teams into the OpenText environment within just six weeks, allowing them to take advantage of the new capabilities rapidly.”**

**Andreas Hofmeyer**  
Product Owner, Regulatory and Quality IT Systems  
Fresenius Kabi

- 5 Knowledge retention** - Prevent critical expertise loss during workforce transitions by capturing implicit knowledge within structured information repositories accessible to remaining teams.
- 6 Submission readiness** - Maintain regulatory submission capabilities throughout restructuring by ensuring continued access to historical submissions and supporting documentation.
- 7 Data-Driven decision-making** - Leverage combined data assets to reveal new insights that inform strategic decisions about product development priorities and market opportunities.
- 8 Integration efficiency** - Accelerate overall restructuring timelines by reducing information-related bottlenecks that typically delay post-merger integration activities.

Learn more about [Driving successful business restructuring in life sciences](#) ›